MiMedx Group Inc
MiMedx Group Inc (MDXG): 10 pipeline candidates · ~10 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
9.6 months
D/E 0.27 · 0% dilution
Lead: Approved
10 candidates
N/A
N/A
A transparent, data-derived signal for MiMedx Group Incacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$548.1M
Cash
$159.8M
Quarterly Burn
$57.4M
Runway
9.6 mo
Revenue
$59.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (10 candidates)
| Drug | Phase |
|---|---|
| AMNIOCORD | Approved |
| AMNIOEFFECT | Approved |
| AMNIOFIX | Approved |
| AXIOFILL | Approved |
| EPICORD | Approved |
| EPICORD Expandable | — |
| EPIEFFECT | Approved |
| EPIFIX | Approved |
| HELIOGEN Fibrillar Collagen Matrix | Approved |
| MiMedx AmnioFix | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
235
Total value held
$438.5M
| Holder | Shares | Value |
|---|---|---|
| essex woodlands management, inc. | 28,195,249 | $111.4M |
| blackrock, inc. | 11,911,300 | $47.0M |
| vanguard capital management llc | 10,332,012 | $40.8M |
| trigran investments, inc. | 7,175,109 | $28.3M |
| state street corp | 5,056,801 | $20.0M |
| paradigm capital management inc/ny | 3,410,300 | $13.5M |
| renaissance technologies llc | 3,019,871 | $11.9M |
| geode capital management, llc | 2,881,159 | $11.4M |
| dimensional fund advisors lp | 2,694,002 | $10.6M |
| punch & associates investment management, inc. | 2,019,718 | $8.0M |
Showing top 10 of 235 institutional holders of MiMedx Group Inc. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in MiMedx Group Inc's pipeline?
MiMedx Group Inc (MDXG) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is MiMedx Group Inc's lead drug candidate?
MiMedx Group Inc's most advanced tracked candidate is AMNIOCORD (Approved) for Surgical settings where an allograft needs to be applied to a deeper area or needs to be sutured in place (provide a protective environment for the healing process).
What is MiMedx Group Inc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, MiMedx Group Inc has approximately 9.6 months of cash runway.
What is MiMedx Group Inc's market capitalization?
MiMedx Group Inc's market capitalization is approximately $548.1M.
Who is the CEO of MiMedx Group Inc?
Mr. Joseph H. Capper is the chief executive officer of MiMedx Group Inc (MDXG).
Get the full picture on MiMedx Group Inc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.